title: Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.
abstract: Over the last two decades, anti-CD20 monoclonal antibody (mAb) therapy has improved patient outcome in B-cell malignancies, and confirmed CD20 as an important target in chronic lymphocytic leukemia (CLL). Until recently, the gold standard was based on the utilization of rituximab combined with chemotherapy (fludarabine and cyclophosphamide), but patients often relapse. Next, with our better understanding of mAb engineering, anti-CD20 mAb therapy has evolved with the development of new mAb permitting significant clinical responses by improving pharmacokinetics, safety, activity and immunogenicity. Last but not least, the development of key tumoral tyrosine kinase inhibitors and their association with anti-CD20 mAb is a work in progress with promising results.
authors.affiliation: Research Unit INSERM ESPRI, ERI29/EA2216 Immunotherapy & B Cell Diseases, Réseau épigénétique et Réseau canaux ioniques du Cancéropôle Grand Ouest, Labex IGO, European University of Brittany, Brest, France.|'Iuliu Hatieganu' University of Medicine & Pharmacy, 8 Babes Street, 400012, Cluj-Napoca, Romania.
authors.forename: Cristina
authors.initials: C
authors.lastname: Bagacean
authors.affiliation: 'Iuliu Hatieganu' University of Medicine & Pharmacy, 8 Babes Street, 400012, Cluj-Napoca, Romania.|'Ion Chiricuta' Institute of Oncology, 34-36 Republicii Street, 400015 Cluj-Napoca, Romania.
authors.forename: Mihnea
authors.initials: M
authors.lastname: Zdrenghea
authors.affiliation: Research Unit INSERM ESPRI, ERI29/EA2216 Immunotherapy & B Cell Diseases, Réseau épigénétique et Réseau canaux ioniques du Cancéropôle Grand Ouest, Labex IGO, European University of Brittany, Brest, France.|Department of Hematology, CHRU Morvan, Brest, France.
authors.forename: Adrian
authors.initials: A
authors.lastname: Tempescul
authors.affiliation: 'Iuliu Hatieganu' University of Medicine & Pharmacy, 8 Babes Street, 400012, Cluj-Napoca, Romania.
authors.forename: Victor
authors.initials: V
authors.lastname: Cristea
authors.affiliation: Research Unit INSERM ESPRI, ERI29/EA2216 Immunotherapy & B Cell Diseases, Réseau épigénétique et Réseau canaux ioniques du Cancéropôle Grand Ouest, Labex IGO, European University of Brittany, Brest, France.|Laboratory of Immunology & Immunotherapy, CHRU Morvan, Brest, France.
authors.forename: Yves
authors.initials: Y
authors.lastname: Renaudineau
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology*; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000628:therapy*; D015202:Protein Engineering; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000069283:Rituximab
keywords: CD20; chronic lymphocytic leukemia; immunotherapy; obinutuzumab; ofatumumab; rituximab